The role of angiogenesis in prostate and other urologic cancers: A review

CMAJ. Canadian Medical Association Journal

Volumn 164, Issue 5, 2001, Pages 662-670

  Izawa, J I ^a   Dinney, C P N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ANGIOGENESIS; BASEMENT MEMBRANE; BLADDER CANCER; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIUM CELL; METASTASIS; MICROVASCULATURE; PHENOTYPE; PROGNOSIS; PROSTATE CANCER; REVIEW; TUMOR GROWTH; URINARY TRACT CANCER;

EID: 0035111069     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (154)

1. Cancer statistics, 2000
2. The pathogenesis of cancer metastasis
3. Biological diversity in metastatic neoplasms: Origins and implications
4. Critical factors in the biology of human cancer metastasis: Twenty-eighth G.H.A. Clowes Memorial Award Lecture
5. The hallmarks of cancer
6. How is blood vessel growth regulated in normal and neoplastic tissue?
7. Induction of angiogenesis during the transition from hyperplasia to neoplasia
8. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
9. The implications of angiogenesis for the biology and therapy of cancer metastasis
10. Clinical applications of research on angiogenesis
11. Anti-angiogenesis: New concept for therapy of solid tumors
12. Tumor growth and neovascularization: An experimental model using the rabbit cornea
13. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
14. Angiogenesis in cancer, vascular, rheumatoid and other disease
15. Cell density-dependent regulation of basic fibroblast growth factor expression in human renal cell carcinoma cells
16. Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice
17. Orthotopic implantation is essential for the selection, growth and metastasis of human renal cell cancer in nude mice
18. Modulation of tumor cell response to chemotherapy by the organ environment
19. Organ-specific angiogenesis and metastases of human bladder carcinoma growing in athymic nude mice
20. The use of molecular genetic markers to demonstrate the effect of organ environment on clonal dominance in a human renal-cell carcinoma grown in nude mice
21. Transgenic mouse models of tumour angiogenesis: The angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models
22. Angiogenic molecules and cancer metastasis
23. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
24. Science, medicine, and the future. Antivascular therapy: A new approach to cancer treatment
25. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
26. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature
27. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
28. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
29. Angiogenic factors expressed by human prostatic cell lines: Effect on endothelial cell growth in vitro
30. Endothelial cell proliferation activity in benign prostatic hyperplasia and prostate cancer: An in vitro model for assessment
31. Angiogenesis and prostate cancer: In vivo and in vitro expression of angiogenesis factors by prostate cancer cells
32. Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique
33. Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor
34. Interleukin-8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer
35. Role of interleukin 10 and transforming growth factor beta1 in the angiogenesis and metastasis of human prostate primary tumor lines from orthotopic implants in severe combined immunodeficiency mice
36. Interleukin 10 (IL-10) inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase (MMP)-2/MMP-9 secretion
37. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue
38. Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts
39. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases
40. UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response
41. Human prostate carcinoma cells express enzymatic activity that converts human plaminogen to the angiogenesis inhibitor, angiostatin
42. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen
43. Antiangiogenic activity of prostate-specific antigen
44. Role of nitric oxide in tumour progression: Lessons from human tumours
45. Nitric oxide synthase inhibition by N(G)-nitro-L-arginine methyl ester inhibits tumor-induced angiogenesis in mammary tumors
46. Selective expression of inducible nitric oxide synthase in human prostate carcinoma
47. Tumor-associated angiogenesis in prostate cancer
48. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting
49. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity
50. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate
51. Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer
52. Significance of tumor angiogenesis in clinically localized prostatic carcinoma treated with external beam radiotherapy
53. CD34 immunohistochemistry assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy
54. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy
55. Microvessel density in prostate cancer: Lack of correlation with tumor grade, pathologic stage, and clinical outcome
56. Role of microvessel density in predicting recurrence in pathologic stage T3 prostatic adenocarcinoma
57. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer
58. Angiogenic peptides in prostatic disease
59. Serum basic fibroblast growth factor in men with and without prostate carcinoma
60. Transforming growth factor β1 is associated with angiogenesis, metastasis, and poorclinical outcome in prostate cancer
61. Expression of platelet-derived endothelial cell growth factor in prostatic adenocarcinoma
62. Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo
63. Angiogenesis inhibitor TNP-470 inhibits growth and metastasis of a hormone-independent rat prostatic carcinoma cell line
64. Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines
65. Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide
66. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic carcinomas
67. Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents
68. Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-β
69. Interferon-α-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule
70. A pharmacokinetically guided phase II study of caroboxyamido-triazole in androgen-independent prostate cancer
71. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation
72. Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression
73. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice
74. Urine from patients with transitional-cell carcinoma stimulates migration of capillary endothelial cells
75. Detection of angiogenesis activity in malignant bladder tissue and cells
76. Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine
77. Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients
78. Two mechanisms of basic fibroblast growth factor-induced angiogenesis in bladder cancer
79. Different angiogenic pathways characterize superficial and invasive bladder cancer
80. The angiogenic factor midkine is expressed in bladder cancer, and overexpression correlates with a poor outcome in patients with invasive cancers
81. Expression of scatter factor in human bladder carcinoma
82. Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder
83. Constitutive production of multiple cytokines and a human chorionic gonadotropin beta-subunit by a human bladder cancer cell line (KU-19-19): Possible demonstration of totipotential differentiation
84. Expression of TGF's beta-1, beta 2 and beta 3 in human bladder carcinomas
85. Thrombospondin-1 expression in bladder cancer: Association with p53 alterations, tumor angiogenesis, and tumor progression
86. Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice
87. Molecular mediators of angiogenesis in bladder cancer
88. Thymidine phosphorylase activity in human bladder cancer: Difference between superficial and invasive cancer
89. Tumor-associated hyaluronic acid: A new sensitive and specific urine marker for bladder cancer
90. Urinary hyaluronic acid and hyaluronidase: Markers for bladder cancer detection and evaluation of grade
91. Identification of bladder tumor-derived hyaluronidase: Its similarity to HYAL1
92. Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas
93. Angiogenesis in bladder cancer: Relationship between microvessel density and tumor prognosis
94. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer
95. Prognostic relevance of micro-vessel density in cancer of the urinary bladder
96. Relationship of tumor angiogenesis and nuclear p53 accumulation in invasive bladder cancer
97. Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder
98. Detection of basic fibroblast growth factor mRNA in urinary bladder cancer: Correlation with local relapses
99. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates
100. Serum concentrations of VEGF and b-FGF in renal cell, prostate and urinary bladder carcinomas
101. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer
102. Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression
103. Expression of vascular endothelial growth factor in primary superficial bladder cancer
104. Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line
105. Increased angiogenin expression in the tumor tissue and serum of urothelial carcinoma patients is related to disease progression and recurrence
106. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-α admininstration
107. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
108. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel
109. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone
110. Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis
111. Detection of tumor angiogenesis factor in adenocarcinoma of kidney
112. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas
113. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis
114. Vascular endothelial growth factor expression is increased in renal cell carcinoma
115. Tubulogenesis by microvascular endothelial cells is mediated by vascular endothelial growth factor (VEGF) in renal cell carcinoma
116. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma
117. Induction of tubulogenesis of microvascular endothelial cells by basic fibroblast growth factor from human SN12C renal cancer cells
118. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggests a suppressor role in kidney, brain, and other human cancers
119. Endothelial and macrophage upregulation of urokinase receptor expression in human renal cell carcinoma
120. Somatic mutations of the von-Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma
121. Mutations of the VHL tumour suppressor gene in renal carcinoma
122. Reversion of deregulated expression of vascular endothelial growth factor in human renal cell carcinoma cells by von Hippel-Lindau tumor suppressor protein
123. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways
124. Transforming growth factor β1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma
125. Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma
126. Microvessel density in renal cell carcinoma: Lack of prognostic signigicance
127. Appraisal of intra-tumoral microvessel density, MIB-1 score, DNA content, and p53 protein expression as prognostic indicators in patients with locally confined renal cell carcinoma
128. Evaluation of microvessel density by computerized image analysis in human renal cell carcinoma. Correlation to pT category, nuclear grade, proliferative activity and occurrence of metastasis
129. Prognostic significance of microvessel count in low stage renal cell carcinoma
130. Clinical significance of tumor angiogenesis in patients with localized renal cell carcinoma
131. Prognostic significance of microscopic vascularity for clear cell renal cell carcinoma
132. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
133. Renal cell carcinoma: Relevance of angiogenic factors
134. Identification of receptor genes in renal cell carcinoma associated with angiogenesis by differential hybridization technique
135. Endostatin: Yeast production, mutants, and antitumor effect in renal cell carcinoma
136. Antitumour effect of a synthetic analogue of fumagillin on murine renal carcinoma
137. Antitumor effects of angiogenesis inhibitor 0-(choroacetyl-carbamoyl) fumagillol (TNP-470) against murine renal cell carcinoma
138. Multi-insitutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma
139. Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon alfa-2b
140. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma
141. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group
142. Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen
143. Multicenter phase II trial of interleukin-2, interferon-alpha, and 13-cis-retinoic acid in patients with metastatic renal-cell carcinoma
144. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: Results of a sequential nonrandomized phase II study
145. A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer
146. Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: A multicenter phase II trial
147. Interferon-alpha and 5-fluorouracil therapy in patients with metastatic renal cell cancer: An open multicenter trial
148. Daily subcutaneous ultra-low-dose interferon-alpha in patients with advanced renal cell carcinoma
149. Continuous-infusion floxuridine and alpha interferon in metastatic renal cancer: A national biotherapy study group phase II study
150. Treatment of renal cancer patients with gemcitabine (2′,2′-difluorodeoxycytidine) and interferons: Antitumor activity and toxicity
151. Preliminary results of the alternating administration of natural interferon-alpha and recombinant interferon-gamma for metastatic renal cell carcinoma
152. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer
153. Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial
154. 3 agents in murine renal cell carcinoma